Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep-Oct;21(5):695-698.
doi: 10.4103/ijem.IJEM_146_17.

Metabolic Derangement in Acute and Chronic Liver Disorders

Sarita Bajaj  1 , Richi Kashyap  1 , Anubha Srivastava  1 , Smriti Singh  1
Affiliations

Metabolic Derangement in Acute and Chronic Liver Disorders

Sarita Bajaj et al. Indian J Endocrinol Metab. 2017 Sep-Oct.

Abstract

Aims: This study aims to assess glycemic and lipid derangement in acute and chronic liver disorders.

Materials and methods: A cross-sectional study was conducted on 104 patients diagnosed with acute or chronic liver disorder. Acute liver disease (ALD) patients were 40 and chronic liver disease (CLD) patients were 64.

Results: The mean value of fasting plasma glucose (FPG) in patients with ALD was 91.8 ± 5.4 mg/dl and in CLD was 115.7 ± 17.9 mg/dl, the difference was significant. The mean value of A1c was 4.3 ± 0.6 in ALD and 6.1 ± 0.8 in CLD, the difference was significant. In patients with CLD mean cholesterol was higher 177.4 ± 28.8 mg/dl when compared to ALD 140 ± 35.1 mg/dl, but the difference was not significant. ALD patients' high-density lipoprotein (HDL) was 50.4 ± 5.1 mg/dl, and in CLD patients, HDL was 44.4 ± 6.1 mg/dl. In CLD mean triglyceride (T) was 148.9 ± 6.4 mg/dl while in ALD T was 134.8 ± 14.2 mg/dl, the difference was significant.

Conclusions: CLD is associated with glycemic derangement demonstrated by deranged FPG and A1c. In patients of ALD, no metabolic derangement was observed.

Keywords: A1c; acute liver disease; chronic liver disease; metabolic derangement.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Anstee Q, Jones D. Liver and biliary tract disease. Davidsons Principles and Practice of Medicine. 22nd ed. Elsevier publication; 2014. pp. 932–3. 959-60.
    1. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120:829–34. - PubMed
    1. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–81. - PubMed
    1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12. - PubMed
    1. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care. 2004;27:1171–5. - PubMed